Tags

Type your tag names separated by a space and hit enter

Pharmacologic treatment options for obesity: what is old is new again.
Curr Hypertens Rep. 2013 Jun; 15(3):182-9.CH

Abstract

After a long period of failure in development, two new medications (phentermine/topiramate ER - Qsymia™ and lorcaserin - Belviq®) have been approved by the US Food and Drug Administration for long-term weight management in persons with obesity (BMI ≥ 30 kg/m(2)) or in overweight persons (BMI ≥ 27 kg/m(2)) with comorbidities. Another medication, bupropion/naltrexone, is undertaking a cardiovascular outcomes trial and an analysis in 2014 will determine its approval and release. The most widely prescribed drug for obesity, phentermine, used since 1959 for short-term weight management, has been released in a new formulation. This paper reviews these new medications, and other important events in the landscape for management of obesity, with an eye to the interests of physicians who manage hypertension. All the new drugs under discussion are re-fittings of old agents or fresh approaches to old targets; thus, what is old is new again in the pharmacotherapy of obesity.

Authors+Show Affiliations

Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808, USA. ryandh@pbrc.eduNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23625271

Citation

Ryan, Donna H., and George A. Bray. "Pharmacologic Treatment Options for Obesity: what Is Old Is New Again." Current Hypertension Reports, vol. 15, no. 3, 2013, pp. 182-9.
Ryan DH, Bray GA. Pharmacologic treatment options for obesity: what is old is new again. Curr Hypertens Rep. 2013;15(3):182-9.
Ryan, D. H., & Bray, G. A. (2013). Pharmacologic treatment options for obesity: what is old is new again. Current Hypertension Reports, 15(3), 182-9. https://doi.org/10.1007/s11906-013-0343-6
Ryan DH, Bray GA. Pharmacologic Treatment Options for Obesity: what Is Old Is New Again. Curr Hypertens Rep. 2013;15(3):182-9. PubMed PMID: 23625271.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacologic treatment options for obesity: what is old is new again. AU - Ryan,Donna H, AU - Bray,George A, PY - 2013/4/30/entrez PY - 2013/4/30/pubmed PY - 2013/12/27/medline SP - 182 EP - 9 JF - Current hypertension reports JO - Curr. Hypertens. Rep. VL - 15 IS - 3 N2 - After a long period of failure in development, two new medications (phentermine/topiramate ER - Qsymia™ and lorcaserin - Belviq®) have been approved by the US Food and Drug Administration for long-term weight management in persons with obesity (BMI ≥ 30 kg/m(2)) or in overweight persons (BMI ≥ 27 kg/m(2)) with comorbidities. Another medication, bupropion/naltrexone, is undertaking a cardiovascular outcomes trial and an analysis in 2014 will determine its approval and release. The most widely prescribed drug for obesity, phentermine, used since 1959 for short-term weight management, has been released in a new formulation. This paper reviews these new medications, and other important events in the landscape for management of obesity, with an eye to the interests of physicians who manage hypertension. All the new drugs under discussion are re-fittings of old agents or fresh approaches to old targets; thus, what is old is new again in the pharmacotherapy of obesity. SN - 1534-3111 UR - https://www.unboundmedicine.com/medline/citation/23625271/Pharmacologic_treatment_options_for_obesity:_what_is_old_is_new_again_ L2 - https://dx.doi.org/10.1007/s11906-013-0343-6 DB - PRIME DP - Unbound Medicine ER -